Teva Pharmaceutical Industries Limited (TEVA) Stake Raised by Scotia Capital Inc.

Scotia Capital Inc. lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 18.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 303,025 shares of the company’s stock after acquiring an additional 46,402 shares during the quarter. Scotia Capital Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $10,065,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries Limited during the 2nd quarter worth about $106,000. Kistler Tiffany Companies LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited during the 1st quarter worth about $123,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after purchasing an additional 100 shares during the last quarter. 56.75% of the stock is currently owned by institutional investors and hedge funds.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.0564% during mid-day trading on Tuesday, hitting $15.7789. 6,711,268 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $45.14. The stock’s market cap is $16.03 billion. The company has a 50-day moving average of $16.87 and a 200 day moving average of $26.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.25 EPS. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.26 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were given a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.16%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Stake Raised by Scotia Capital Inc.” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/10/10/teva-pharmaceutical-industries-limited-teva-stake-raised-by-scotia-capital-inc.html.

Several research analysts recently weighed in on TEVA shares. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating and set a $31.05 price target for the company. in a research report on Monday, June 12th. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th. Mizuho upgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and upped their price target for the stock from $25.00 to $30.00 in a research report on Thursday, June 15th. Cantor Fitzgerald started coverage on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, June 15th. They set a “neutral” rating and a $31.00 price target for the company. Finally, Royal Bank Of Canada set a $38.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Friday, June 16th. Five investment analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $27.63.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit